A bi-specific T-cell engager (BiTE®) is a novel type of engineered molecule used for the treatment of cancer. These molecules harness and activate T-cells, which are involved in the body’s immune response, to attack tumor cells. There is currently one FDA-approved BiTE® therapy treatment for targeting small cell lung cancer (SCLC).
The video below was created to give you clear, easy-to-understand information about bi-specific T-cell engages, so you can feel more informed and prepared as you talk with your care team about whether this treatment could be right for you.
Use this PDF to start a conversation with your care team to see if BiTE® therapy might be helpful for you.